#Cristcot
Cristcot Unveils Promising Findings on Innovative Ulcerative Colitis Therapy at ACG 2025#USA#Austin#Ulcerative_Colitis#Cristcot#HCA_Therapy
Cristcot Unveils Promising Findings on Innovative Ulcerative Colitis Therapy at ACG 2025
Cristcot reveals pivotal clinical findings on their new ulcerative colitis treatment at the ACG 2025 Annual Meeting, showcasing significant efficacy.
third-news.com
October 26, 2025 at 7:07 PM
Cristcot's Major Engagement at the 2025 GI ReConnect Annual Meeting: A Leap Forward in Gastroenterology#USA#Ulcerative_Colitis#Cristcot#GI_ReConnect#Aurora,_Colorado
Cristcot's Major Engagement at the 2025 GI ReConnect Annual Meeting: A Leap Forward in Gastroenterology
Cristcot showcased its commitment to gastrointestinal health by actively participating in the 2025 GI ReConnect meeting, emphasizing advancements in ulcerative colitis treatment.
third-news.com
June 24, 2025 at 11:14 AM
Cristcot Hires Richard Kim as CCO to Drive Commercialization Strategy for New Treatments#USA#Ulcerative_Colitis#Concord#Cristcot#Richard_Kim
Cristcot Hires Richard Kim as CCO to Drive Commercialization Strategy for New Treatments
Richard Kim has been appointed Chief Commercial Officer at Cristcot, leading efforts to bring innovative therapies for gastrointestinal diseases to market.
third-news.com
June 10, 2025 at 11:20 AM
Cristcot's Phase 3 Trial Shows Promise for Hydrocortisone Acetate Suppository in Ulcerative Colitis Treatment#United_States#Hydrocortisone#Cristcot#Sephure#Concord,_Massachusetts
Cristcot's Phase 3 Trial Shows Promise for Hydrocortisone Acetate Suppository in Ulcerative Colitis Treatment
Cristcot has achieved encouraging results in its Phase 3 trial for a hydrocortisone acetate suppository designed to treat ulcerative colitis, showing potential for rapid symptom relief.
third-news.com
January 9, 2025 at 12:35 PM
@rbly.bsky.social and to Robin's point - a recent clinical trial of a formulation of hydrocortisone for UC went awry when HPA axis evals via periodic ACTH-stim testing during the trial revealed that participants were surreptitiously using prednisone. 27% in the PBO arm, 5% in the drug arm.
Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)
Oral presentation on the impact of concomitant steroid use in ulcerative colitis (UC) scheduled for May 5, 2026, at 9:30am CDT...
www.globenewswire.com
May 13, 2026 at 10:55 AM